ZEPOSIA was studied in the largest number of patients with RMS in 2 pivotal head-to-head trials against an active comparator (N=2659)2,3a:
POWERFUL
Efficacy1b
Proven superior in reducing
relapses vs Avonexc
Proven superior in reducing GdE
and T2 lesions vs Avonex
COMPARABLE Safety Profile vs Avonex in Overall Incidence of Adverse Reactions1-3d
Consistently low discontinuation
rates vs Avonex
Comparable rates of serious infections and malignancies vs Avonex
The FIRST AND ONLY S1P With No First-Dose Observation Required1,4,5e
Full Prescribing Information for ZEPOSIA has
NO FIRST-DOSE OBSERVATION required
NO genetic testing required
NO ophthalmic testing required for most patients6f